<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000892</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 359</org_study_id>
    <secondary_id>11324</secondary_id>
    <nct_id>NCT00000892</nct_id>
  </id_info>
  <brief_title>A Study of Several Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Used Indinavir</brief_title>
  <official_title>Activity of the Soft Gelatin Capsule of Saquinavir (SQVsgc) in Combination With Ritonavir or Nelfinavir and Combinations of Delavirdine and/or Adefovir Dipivoxil in HIV-Infected Subjects With Prior Indinavir Use and Viral Loads From 2,000 to 200,000 Copies HIV RNA/ml</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To compare the proportion of patients whose plasma HIV-1 RNA is below 500 copies/ml after 16
      weeks of treatment. To assess the safety, toxicity, and tolerance of each treatment arm.

      While indinavir is currently the most commonly prescribed protease inhibitor, the optimal
      therapy for a person on an indinavir-containing regimen who experiences a rebound in viral
      load or never experiences a decrease in viral load below 500 copies per milliliter is
      unknown. Current clinical practice for such patients typically involves empiric use of a
      combination of other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir) and
      at least 1 other antiretroviral agent to which the patient has had little or no prior
      exposure. This may involve the use of 1 or more reverse transcriptase inhibitors (RTIs) or
      nonnucleoside reverse transcriptase inhibitors (NNRTIs). This study attempts to formally
      evaluate some of these options in indinavir-experienced patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      While indinavir is currently the most commonly prescribed protease inhibitor, the optimal
      therapy for a person on an indinavir-containing regimen who experiences a rebound in viral
      load or never experiences a decrease in viral load below 500 copies per milliliter is
      unknown. Current clinical practice for such patients typically involves empiric use of a
      combination of other protease inhibitors (saquinavir/nelfinavir or saquinavir/ritonavir) and
      at least 1 other antiretroviral agent to which the patient has had little or no prior
      exposure. This may involve the use of 1 or more reverse transcriptase inhibitors (RTIs) or
      nonnucleoside reverse transcriptase inhibitors (NNRTIs). This study attempts to formally
      evaluate some of these options in indinavir-experienced patients.

      Patients are stratified by HIV RNA (2,000 - 20,000 copies/ml versus 20,000 - 200,000
      copies/ml), and randomized to 1 of 6 treatment arms as follows:

      Arm A: Saquinavir (SQV) plus ritonavir (RTV) plus delavirdine (DLV) plus adefovir dipivoxil
      placebo.

      Arm B: SQV plus RTV plus DLV placebo plus adefovir dipivoxil. Arm C: SQV plus RTV plus DLV
      plus adefovir dipivoxil. Arm D: SQV plus nelfinavir (NFV) plus DLV plus adefovir dipivoxil
      placebo. Arm E: SQV plus NFV plus DLV placebo plus adefovir dipivoxil. Arm F: SQV plus NFV
      plus DLV plus adefovir dipivoxil. In addition to assigned study treatment patients receive an
      L-carnitine supplement.

      Therapy is administered for 24 weeks. Patients who have an average HIV RNA value for Weeks 12
      and 16 that is less than 5,000 copies or a least 1 log below their baseline value may
      continue their assigned study treatment for an additional 24 weeks. [AS PER AMENDMENT
      3/30/98: Subjects with plasma HIV RNA greater than 5,000 copies/ml may elect to continue or
      discontinue study medications in the treatment extension and seek the best available
      treatment.] [AS PER AMENDMENT 06/11/98: The dose of adefovir dipivoxil is reduced at or after
      Week 16. Alternatively, patients may discontinue adefovir dipivoxil/placebo and substitute
      appropriate antiretroviral agent(s) or add appropriate antiretroviral agent(s) to their
      reduced-dose regimen. Also, at the discretion of the protocol chairperson, patients who have
      been on study for more than 16 weeks may substitute appropriate FDA-approved antiretroviral
      agent(s) for any study medication that must be discontinued because of toxicity. Addition of
      nonnucleoside reverse transcriptase inhibitors, protease inhibitors, or investigational
      agents is specifically excluded.]
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">August 1999</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nelfinavir mesylate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levocarnitine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saquinavir</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Delavirdine mesylate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Required:

          -  Chemoprophylaxis for Pneumocystis carinii pneumonia for all patients who have a CD4
             cell count of equal or less than 200 cells/mm3.

        Allowed:

          -  Topical and oral antifungal agents except ketoconazole and itraconazole.

          -  Treatment, maintenance or chemoprophylaxis with approved agents for opportunistic
             infections.

          -  Antibiotics.

          -  Systemic corticosteroids for 21 days or less for acute problems.

          -  Recombinant erythropoietin (rEPO) and granulocyte-colony stimulating factor (G-CSF,
             filgrastim).

          -  Regularly prescribed medications such as antipyretics, analgesics, allergy
             medications, antidepressants, sleep medications, oral contraceptives (not as a sole
             form of birth control), megestrol acetate, or testosterone.

          -  Alternative therapies, such as vitamins, acupuncture, and visualization techniques.

          -  [AS PER AMENDMENT 3/30/98: Calcium channel blockers may be used only with caution.]

        Patients must have:

          -  HIV-1 infection documented by a licensed ELISA and confirmed by Western blot, HIV
             culture, HIV antigen, plasma HIV RNA, or a second antibody test other than ELISA.

          -  2,000 to 200,000 HIV-1 RNA copies/ml as measured by any Roche-certified laboratory [AS

        PER AMENDMENT 3/30/98:

          -  using the Roche Amplicor HIV-1 Monitor] within 30 days of study entry.

          -  Signed, informed consent from parent or legal guardian for patients less than 18 years
             of age.

        Prior Medication: Required:

          -  More than 6 months cumulative indinavir therapy.

          -  Stable indinavir-containing antiretroviral regimen for at least 4 weeks [2 weeks AS
             PER AMENDMENT 3/30/98] prior to study entry.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Any active infection requiring acute treatment within 30 days [21 days AS PER
             AMENDMENT 3/30/98] prior to study entry.

          -  Unexplained temperature greater than 38.5 degrees for any 7 consecutive days within 30
             days prior to study entry.

          -  Malignancy, including Kaposi's sarcoma, that requires systemic chemotherapy.

        Concurrent Medication:

        Excluded:

          -  Non-protocol-specified immunomodulatory and/or antiretroviral agents.

          -  Systemic cytotoxic chemotherapy.

          -  Ketoconazole, itraconazole, rifampin, rifabutin, alprazolam, amiodarone, astemizole,
             bepridil, bupropion, cisapride, clorazepate, clozapine, diazepam, encainide,
             estazolam, flecainide, flurazepam, isotretinoin, meperidine, midazolam, piroxicam,
             propafenone, propoxyphene, quinidine, terfenadine, triazolam, zolpidem, phenytoin,
             phenobarbital, carbamazepine, and ergot alkaloids and [ AS PER AMENDMENT 3/30/98:
             dexamethasone, ergot derivatives, and pimozide].

        Avoided:

          -  Herbal medications.

        Prior Medication:

        Excluded:

          -  At least 2 weeks or more total ritonavir and/or saquinavir (hard gelatin capsule).

          -  NNRTIs (nevirapine, delavirdine, DMP-266, etc.), saquinavir (soft gelatin capsule),
             nelfinavir, 141W94VX-478, and adefovir dipivoxil.

          -  Immunomodulator [systemic immunomodulator AS PER AMENDMENT 3/30/98] or investigational
             drug therapy within 30 days prior to entry.

          -  Active immunization within 30 days [21 days AS PER AMENDMENT 3/30/98] prior to entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>R Gulick</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>D Katzenstein</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Southern California / LA County USC Med Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900331079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Willow Clinic</name>
      <address>
        <city>Menlo Park</city>
        <state>California</state>
        <zip>94025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of California / San Diego Treatment Ctr</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>921036325</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Francisco Gen Hosp</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>941102859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford at Kaiser / Kaiser Permanente Med Ctr</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>951282699</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Mateo AIDS Program / Stanford Univ</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Univ Med Ctr</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>943055107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA Med Ctr</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Health Sciences Ctr</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Univ</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>331361013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queens Med Ctr</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Hawaii</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern Univ Med School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cook County Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Presbyterian - Saint Luke's Med Ctr</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis A Weiss Memorial Hosp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ Hosp</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>462025250</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Methodist Hosp of Indiana / Life Care Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State of MD Div of Corrections / Johns Hopkins Univ Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>212052196</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Hosp</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Med Ctr</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess - West Campus</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY / Erie County Med Ctr at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bellevue Hosp / New York Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell Univ Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Med Ctr</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>275997215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>452670405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State Univ Hosp Clinic</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>432101228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pennsylvania at Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Pittsburgh Med Ctr</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brown Univ School of Medicine</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Julio Arroyo</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Texas Galveston</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>775550435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>981224304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gulick RM, Hu XJ, Fiscus S, Fletcher CV, Haubrich R, Cheng H, Lagakos S, Acosta E, Swanstrom R, Mills C, Snyder S, Fischl M, Pettinelli C, Katzenstein D. Durability of salvage therapy with saquinavir SGC (SQV) in combination with ritonavir (RTV) or nelfinavir (NFV) plus delavirdine (DLV), adefovir dipivoxil (ADV), or both; ACTG 359: 48-week final results. 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 338)</citation>
  </reference>
  <reference>
    <citation>Acosta EP, Gulick R, Katzenstein D, Haubrich R, Fischl M, Raasch R, Mills C, Pettinelli C, Remmel RP, Fletcher CV. Pharmacokinetic (PK) evaluation of saquinavir soft gel capsules (SQV)/ritonavir (RTV) or sqv/nelfinavir (NFV) in combination with delavirdine (DLV) and/or adefovir dipivoxil (ADV) - - ACTG 359. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:136 (abstract no 365)</citation>
  </reference>
  <reference>
    <citation>Gulick RM, et al. Salvage therapy with saquinavir sgc (SQV) in combination with ritonavir (RTV) or nelfinavir (NFV) and delavirdine (DLV), adefovir dipivoxil (ADV), or both-ACTG 359. Second International Workshop on Salvage Therapy for HIV Infection. 1999 May 19-21</citation>
  </reference>
  <reference>
    <citation>Fletcher CV, Testa MA, Haubrich R, Brundage R, Jiang H, Ickovics J, Martinez A, Snyder S, Gulick R. Relationships among Four Measures of Medication Adherence and Virologic Response in ACTG 359. 10th Conference on Retroviruses and Oppurtunistic Infections. Feb 2003. Abstract 577.</citation>
  </reference>
  <results_reference>
    <citation>Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in human immunodeficiency virus-infected adults with virologic failure on indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000 Nov;182(5):1375-84. Epub 2000 Oct 9.</citation>
    <PMID>11023461</PMID>
  </results_reference>
  <results_reference>
    <citation>Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich R, Cheng H, Acosta E, Lagakos SW, Swanstrom R, Freimuth W, Snyder S, Mills C, Fischl M, Pettinelli C, Katzenstein D. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359. J Infect Dis. 2002 Sep 1;186(5):626-33. Epub 2002 Aug 9.</citation>
    <PMID>12195349</PMID>
  </results_reference>
  <results_reference>
    <citation>Fletcher CV, Jiang H, Brundage RC, Acosta EP, Haubrich R, Katzenstein D, Gulick RM. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004 Apr 1;189(7):1176-84. Epub 2004 Mar 16.</citation>
    <PMID>15031785</PMID>
  </results_reference>
  <results_reference>
    <citation>Swanstrom R, Bosch RJ, Katzenstein D, Cheng H, Jiang H, Hellmann N, Haubrich R, Fiscus SA, Fletcher CV, Acosta EP, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team. Weighted phenotypic susceptibility scores are predictive of the HIV-1 RNA response in protease inhibitor-experienced HIV-1-infected subjects. J Infect Dis. 2004 Sep 1;190(5):886-93. Epub 2004 Jul 23.</citation>
    <PMID>15295692</PMID>
  </results_reference>
  <results_reference>
    <citation>Fletcher CV, Testa MA, Brundage RC, Chesney MA, Haubrich R, Acosta EP, Martinez A, Jiang H, Gulick RM. Four measures of antiretroviral medication adherence and virologic response in AIDS clinical trials group study 359. J Acquir Immune Defic Syndr. 2005 Nov 1;40(3):301-6.</citation>
    <PMID>16249704</PMID>
  </results_reference>
  <results_reference>
    <citation>Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM; AIDS Clinical Trials Group Protocol 359 Team. Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359. HIV Clin Trials. 2007 Mar-Apr;8(2):63-7.</citation>
    <PMID>17507321</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>July 26, 2013</last_update_submitted>
  <last_update_submitted_qc>July 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Indinavir</keyword>
  <keyword>RNA, Viral</keyword>
  <keyword>Saquinavir</keyword>
  <keyword>Delavirdine</keyword>
  <keyword>Nelfinavir</keyword>
  <keyword>Adenine</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <keyword>Viral Load</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Nelfinavir</mesh_term>
    <mesh_term>Indinavir</mesh_term>
    <mesh_term>Saquinavir</mesh_term>
    <mesh_term>Delavirdine</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

